Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)

ClinicalTrials.gov ID: NCT01946880

Public ClinicalTrials.gov record NCT01946880. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 6, 2026, 2:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This trial seeks to describe the effect of withdrawal from mycophenolate mofetil (MMF) on risk of clinically significant disease reactivation in quiescent SLE patients who have been on long-term MMF therapy.

Study identification

NCT ID: NCT01946880
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Enrollment: 102 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 70 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 19, 2013
Primary completion: Jul 2, 2019
Completion: Jul 2, 2019
Last update posted: Aug 16, 2020

2013 – 2019

United States locations

U.S. sites: 19
U.S. states: 14
U.S. cities: 18

Facility	City	State	ZIP	Site status
Cedars-Sinai Medical Center	Los Angeles	California	90048	—
UCSD	San Diego	California	92093-0943	—
UCSF School of Medicine	San Francisco	California	94143-0633	—
University of Colorado	Denver	Colorado	80204	—
University of Miami Hospitals and Clinics	Miami	Florida	33136	—
Emory University	Atlanta	Georgia	30303	—
University of Chicago	Chicago	Illinois	60637-1426	—
Brigham & Women's Hospital	Boston	Massachusetts	02115	—
University of Michigan	Ann Arbor	Michigan	48109	—
University of Mississippi Medical Center	Jackson	Mississippi	39216	—
Feinstein Institute for Medical Research	Manhasset	New York	11025	—
New York University, Langone Medical Center	New York	New York	10016	—
Weill Cornell Medical College: Hospital for Special Surgery - Rheumatology Division	New York	New York	10021	—
University of Rochester Medical Center	Rochester	New York	14642	—
Duke University Medical Center	Durham	North Carolina	27710	—
The Ohio State University Wexner Medical Center	Columbus	Ohio	43210	—
Oklahoma Medical Research Foundation	Oklahoma City	Oklahoma	73104	—
Penn State University	Hershey	Pennsylvania	17033	—
Medical University of South Carolina	Charleston	South Carolina	29412	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01946880, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 16, 2020 · Synced Sep 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01946880 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →